Nilo Azad
Expertise in
17
conditions

Dr. Nilo Azad

Oncology
Johns Hopkins Medicine
Skip Viragh Outpatient Cancer Center
201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
Offers Telehealth

Expertise in
17
conditions
Johns Hopkins Medicine
Skip Viragh Outpatient Cancer Center
201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board.

Dr. Azad is highly rated in 17 conditions, according to our data. Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Colonoscopy.

Her clinical research consists of co-authoring 155 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
Baylor College of Medicine, Internal Medicine, 2004
Specialties
Oncology
Licenses
Internal Medicine in MD
Board Certifications
American Board Of Internal Medicine
Fellowships
National Institutes of Health Clinical Center, Oncology and Hematology, 2008
Hospital Affiliations
Sibley Memorial Hospital
The Johns Hopkins Hospital
Languages Spoken
English
Hindi
Urdu
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Skip Viragh Outpatient Cancer Center
201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, Baltimore, MD 21287
Call: 410-955-8964

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


17 Clinical Trials

A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors
A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Phase: Phase 1
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Procedure
Study Drug: Olaparib
Study Phase: Phase 2
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: January 12, 2026
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer
A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Biological, Drug
Study Drugs: Durvalumab, Guadecitabine
Study Phase: Phase 1
A Study of Using Epigenetic Modulators to Enhance Response to MK-3475 in Microsatellite Stable Advanced Colorectal Cancer
A Study of Using Epigenetic Modulators to Enhance Response to MK-3475 in Microsatellite Stable Advanced Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 03, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors
A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug, Procedure
Study Drugs: Ceralasertib, Olaparib
Study Phase: Phase 2
Phase II Study to Evaluate Stereotactic Body Radiation Therapy For Palliative Management of Unresectable Recurrent or Residual Pancreatic or Periampullary Adenocarcinoma
Phase II Study to Evaluate Stereotactic Body Radiation Therapy For Palliative Management of Unresectable Recurrent or Residual Pancreatic or Periampullary Adenocarcinoma
Enrollment Status: Completed
Publish Date: July 20, 2025
Intervention Type: Radiation
Study Phase: Phase 2
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Atezolizumab, Cobimetinib, Varlilumab
Study Phase: Phase 2
A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers
A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Biological, Drug
Study Drugs: INT230-6, Pembrolizumab, Ipilimumab
Study Phase: Phase 1/Phase 2
A Phase II Clinical Trial of GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients With Borderline Resectable Pancreatic Adenocarcinoma
A Phase II Clinical Trial of GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients With Borderline Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug, Radiation
Study Drugs: Cyclophosphamide, Nivolumab, GVAX Pancreas Vaccine
Study Phase: Phase 2
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Cobimetinib
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin
Study Phase: Phase 2/Phase 3
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
Enrollment Status: Completed
Publish Date: October 25, 2023
Intervention Type: Drug
Study Drug: M7824
Study Phase: Phase 2
A Phase II Trial to Improve Outcomes in Patients With Resected Pancreatic Adenocarcinoma at High Risk for Recurrence Using Epigenetic Therapy
A Phase II Trial to Improve Outcomes in Patients With Resected Pancreatic Adenocarcinoma at High Risk for Recurrence Using Epigenetic Therapy
Enrollment Status: Completed
Publish Date: October 04, 2022
Intervention Type: Drug, Other
Study Drugs: Azacitidine, First-line chemotherapy after recurrence
Study Phase: Phase 2
A Phase 1 Study of Alisertib (MLN8237) in Combination With mFOLFOX in Gastrointestinal Tumors
A Phase 1 Study of Alisertib (MLN8237) in Combination With mFOLFOX in Gastrointestinal Tumors
Enrollment Status: Completed
Publish Date: October 09, 2018
Intervention Type: Drug, Other
Study Phase: Phase 1
View 16 Less Clinical Trials

155 Total Publications

Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.
Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 27, 2025
View All 155 Publications
Similar Doctors
Matthias Holdhoff
Expertise in
19
conditions
Dr. Matthias Holdhoff
Oncology
Expertise in
19
conditions
Dr. Matthias Holdhoff
Oncology

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
 (1.2 miles away)
410-955-8964
Languages Spoken:
English, German
See accepted insurances
Offers Telehealth

Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is highly rated in 19 conditions, according to our data. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.

Expertise in
18
conditions
Dr. Taofeek Owonikoko
Hematology | Oncology
Expertise in
18
conditions
Dr. Taofeek Owonikoko
Hematology | Oncology

Office

22 S Greene St # 9, 
Baltimore, MD 
 (1.6 miles away)
410-328-6841
Languages Spoken:
English
See accepted insurances

Taofeek Owonikoko is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Owonikoko is highly rated in 18 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.

Expertise in
16
conditions
Dr. Stuart Grossman
Oncology
Expertise in
16
conditions
Dr. Stuart Grossman
Oncology

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
 (1.2 miles away)
410-955-8964
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stuart Grossman, M.D., is a professor of oncology at the Johns Hopkins Kimmel Cancer Center. He has served as Principal Investigator and Director of the Central Operations office of the National Cancer Institute-funded phase I/II brain tumor consortia (New Approaches to Brain Tumor Therapy CNS Consortium and the Adult Brain Tumor Consortium) for the past 22 years. He has led many phase I, II, and III institutional and cooperative group translational and clinical brain cancer research projects. Dr. Grossman's expertise is in brain cancers, translational and clinical research, and directing large, multicenter, multidisciplinary clinical trial groups and training programs. Dr. Grossman was an intern and resident at Strong Memorial Hospital in Rochester, NY, and a fellow at the Johns Hopkins University School of Medicine. He received his M.D. from the University of Rochester. Dr. Grossman is highly rated in 16 conditions, according to our data. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri.

VIEW MORE Oncologists

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Azad's expertise for a condition
ConditionClose
  • Elite
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Azad is
    Elite
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
  • Colorectal Cancer
    Dr. Azad is
    Elite
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Pancreatic Cancer
    Dr. Azad is
    Elite
    . Learn about Pancreatic Cancer.
    See more Pancreatic Cancer experts
  • Distinguished
  • Familial Colorectal Cancer
    Dr. Azad is
    Distinguished
    . Learn about Familial Colorectal Cancer.
    See more Familial Colorectal Cancer experts
  • Familial Pancreatic Cancer
    Dr. Azad is
    Distinguished
    . Learn about Familial Pancreatic Cancer.
    See more Familial Pancreatic Cancer experts
  • Gallbladder Adenocarcinoma
    Dr. Azad is
    Distinguished
    . Learn about Gallbladder Adenocarcinoma.
    See more Gallbladder Adenocarcinoma experts
  • Gallbladder Cancer
    Dr. Azad is
    Distinguished
    . Learn about Gallbladder Cancer.
    See more Gallbladder Cancer experts
  • Gastroesophageal Junction Cancer
    Dr. Azad is
    Distinguished
    . Learn about Gastroesophageal Junction Cancer.
    See more Gastroesophageal Junction Cancer experts
  • Lynch Syndrome
    Dr. Azad is
    Distinguished
    . Learn about Lynch Syndrome.
    See more Lynch Syndrome experts
  • Advanced
  • Bladder Cancer
    Dr. Azad is
    Advanced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Gallbladder Disease
    Dr. Azad is
    Advanced
    . Learn about Gallbladder Disease.
    See more Gallbladder Disease experts
  • Liver Cancer
    Dr. Azad is
    Advanced
    . Learn about Liver Cancer.
    See more Liver Cancer experts
  • Muscle Invasive Bladder Cancer
    Dr. Azad is
    Advanced
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Neuroendocrine Tumor
    Dr. Azad is
    Advanced
    . Learn about Neuroendocrine Tumor.
    See more Neuroendocrine Tumor experts
  • Non-Muscle Invasive Bladder Cancer
    Dr. Azad is
    Advanced
    . Learn about Non-Muscle Invasive Bladder Cancer.
    See more Non-Muscle Invasive Bladder Cancer experts
View All 8 Advanced Conditions
  • Experienced
  • Adult Soft Tissue Sarcoma
    Dr. Azad is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Ampullary Cancer
    Dr. Azad is
    Experienced
    . Learn about Ampullary Cancer.
    See more Ampullary Cancer experts
  • Anal Cancer
    Dr. Azad is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Astrocytoma
    Dr. Azad is
    Experienced
    . Learn about Astrocytoma.
    See more Astrocytoma experts
  • Brain Tumor
    Dr. Azad is
    Experienced
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Camurati-Engelmann Disease
    Dr. Azad is
    Experienced
    . Learn about Camurati-Engelmann Disease.
    See more Camurati-Engelmann Disease experts
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
  1. Homepage
  2. Oncologists Baltimore, MD
  3. Dr. Nilo Azad
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    Once you submit your request, MediFind will reach out to the provider’s office to help schedule your appointment. Note that this is not a confirmed booking. You’ll receive a status update via email within 1–2 business days.

    Patient Details

    This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.